Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, April 18, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

PHOENIX - Insys Therapeutics boosted its stock price with false and misleading statements about its "unethical off-label marketing," and the share price fell from $45.28 to $37.55 in a day when the truth came out, then fell another $9.88, shareholders claim in Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...